Patents by Inventor Eckard Wimmer
Eckard Wimmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12054749Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.Type: GrantFiled: June 2, 2022Date of Patent: August 6, 2024Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, The Research Foundation for the State University of New YorkInventors: Peter L. Collins, Cyril Le Nouen, Linda G. Brock, Ursula J. Buchholz, Joshua Marc Dinapoli, Steffen Mueller, Eckard Wimmer
-
Publication number: 20240228981Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.Type: ApplicationFiled: November 17, 2023Publication date: July 11, 2024Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
-
Publication number: 20240228978Abstract: This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.Type: ApplicationFiled: April 1, 2024Publication date: July 11, 2024Applicant: The Research Foundation for the State of University New YorkInventors: Steffen Mueller, Eckard Wimmer, Bruce Futcher, Steve Skiena, Chen Yang
-
Patent number: 11549101Abstract: This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.Type: GrantFiled: June 10, 2019Date of Patent: January 10, 2023Assignee: The Research Foundation for State University of New YorkInventors: Steffen Mueller, Eckard Wimmer, Bruce Futcher, Steven Skiena, Chen Yang
-
Publication number: 20220325252Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.Type: ApplicationFiled: June 2, 2022Publication date: October 13, 2022Inventors: Peter L. COLLINS, Cyril LE NOUEN, Linda G. BROCK, Ursula J. BUCHHOLZ, Joshua Marc DINAPOLI, Steffen MUELLER, Eckard WIMMER
-
Publication number: 20220298492Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.Type: ApplicationFiled: October 28, 2021Publication date: September 22, 2022Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
-
Patent number: 11371024Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.Type: GrantFiled: March 16, 2018Date of Patent: June 28, 2022Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Peter L. Collins, Cyril Le Nouën, Linda G. Brock, Ursula J. Buchholz, Joshua Marc DiNapoli, Steffen Mueller, Eckard Wimmer
-
Patent number: 11162080Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.Type: GrantFiled: July 16, 2018Date of Patent: November 2, 2021Assignee: The Research Foundation for The State University of New YorkInventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
-
Publication number: 20210009962Abstract: This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.Type: ApplicationFiled: June 10, 2019Publication date: January 14, 2021Inventors: Steffen Mueller, Eckard Wimmer, Bruce Futcher, Steven Skiena, Chen Yang
-
Patent number: 10400220Abstract: This invention provides an attenuated virus comprising a modified viral genome engineered to containing multiple nucleotide substitutions that reduce the codon pair bias of a virus protein encoding sequence relative to a first host while the codon pair bias relative to a second host is not substantially reduced. In another embodiment, the invention provides an attenuated virus comprising modified viral genome engineered to containing multiple nucleotide substitutions that reduce the codon pair bias of a virus protein-encoding sequence relative to a first host and a second host. The attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the attenuated virus.Type: GrantFiled: September 8, 2015Date of Patent: September 3, 2019Assignee: The Research Foundation for The State University of New YorkInventors: Eckard Wimmer, Steffen Mueller, Bruce Futcher, Sam Shen, Charles Stauft, Charles Ward
-
Patent number: 10316294Abstract: This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.Type: GrantFiled: March 15, 2014Date of Patent: June 11, 2019Assignee: The Research Foundation for The State University of New YorkInventors: Steffen Mueller, Eckard Wimmer, Bruce Futcher, Steven Skiena, Chen Yang
-
Publication number: 20190169235Abstract: This invention provides a modified protein encoding sequence containing nucleotide substitutions at multiple locations in the protein encoding sequence, wherein the substitutions introduce rare hexamers. These hexamers may be Frame Dependent, or depleted in only the reading frame, or Frame Independent, or depleted in all three frames. Modified protein encoding se quences of the present invention may include modified viruses useful for vaccines.Type: ApplicationFiled: November 7, 2016Publication date: June 6, 2019Inventors: Bruce Futcher, Justin Gardin, Steven Skiena, Alisa Yurovsky, Eckard Wimmer, Steffen Mueller
-
Publication number: 20190010469Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.Type: ApplicationFiled: July 16, 2018Publication date: January 10, 2019Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
-
Publication number: 20190002837Abstract: This invention provides an attenuated virus comprising a modified viral genome engineered to containing multiple nucleotide substitutions that reduce the codon pair bias of a virus protein encoding sequence relative to a first host while the codon pair bias relative to a second host is not substantially reduced. In another embodiment, the invention provides an attenuated virus comprising modified viral genome engineered to containing multiple nucleotide substitutions that reduce the codon pair bias of a virus protein-encoding sequence relative to a first host and a second host. The attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the attenuated virus.Type: ApplicationFiled: September 8, 2015Publication date: January 3, 2019Applicant: The Research Foundation for The State University of New YorkInventors: Eckard Wimmer, Steffen Mueller, Bruce Futcher, Sam Shen, Charles Stauft, Charles Ward
-
Publication number: 20180208906Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.Type: ApplicationFiled: March 16, 2018Publication date: July 26, 2018Inventors: Peter L. Collins, Cyril Le Nouën, Linda G. Brock, Ursula J. Buchholz, Joshua Marc DiNapoli, Steffen Mueller, Eckard Wimmer
-
Patent number: 10023845Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.Type: GrantFiled: September 7, 2016Date of Patent: July 17, 2018Assignee: The Research Foundation for The State University of New YorkInventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
-
Patent number: 9957486Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.Type: GrantFiled: February 7, 2014Date of Patent: May 1, 2018Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Research Foundation For the State University of New YorkInventors: Peter L. Collins, Cyril Le Nouën, Linda G. Brock, Ursula J. Buchholz, Joshua Marc DiNapoli, Steffen Mueller, Eckard Wimmer
-
Publication number: 20170067030Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.Type: ApplicationFiled: September 7, 2016Publication date: March 9, 2017Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
-
Patent number: 9476032Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.Type: GrantFiled: March 31, 2008Date of Patent: October 25, 2016Assignee: The Research Foundation for The State University of New YorkInventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
-
Publication number: 20160024477Abstract: This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.Type: ApplicationFiled: March 15, 2014Publication date: January 28, 2016Inventors: Steffen MUELLER, Eckard WIMMER, Bruce FUTCHER, Steven SKIENA, Chen YANG